182 related articles for article (PubMed ID: 37188737)
1. TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Wei J; Wang L; Zhang Y; Sun T; Zhang C; Hu Z; Zhou L; Liu X; Wan J; Ma L
Oncogene; 2023 Jun; 42(26):2103-2112. PubMed ID: 37188737
[TBL] [Abstract][Full Text] [Related]
2. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.
Liu Y; Tao S; Liao L; Li Y; Li H; Li Z; Lin L; Wan X; Yang X; Chen L
Nat Commun; 2020 Jan; 11(1):348. PubMed ID: 31953436
[TBL] [Abstract][Full Text] [Related]
3. TRIM25 promotes glioblastoma cell growth and invasion via regulation of the PRMT1/c-MYC pathway by targeting the splicing factor NONO.
Chen Y; Xu X; Ding K; Tang T; Cai F; Zhang H; Chen Z; Qi Y; Fu Z; Zhu G; Dou Z; Xu J; Chen G; Wu Q; Ji J; Zhang J
J Exp Clin Cancer Res; 2024 Feb; 43(1):39. PubMed ID: 38303029
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
[TBL] [Abstract][Full Text] [Related]
5. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Deng Y; Zhu H; Xiao L; Liu C; Meng X
Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Cai Y; Gu WT; Cheng K; Jia PF; Li F; Wang M; Zhang WF; Qiu JT; Wu ZB; Zhao WG
Biochem Biophys Res Commun; 2021 Apr; 550():134-141. PubMed ID: 33691199
[TBL] [Abstract][Full Text] [Related]
7. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
9. PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Zhou L; Huang X; Zhang Y; Wang J; Li H; Huang H
Brain Behav; 2022 May; 12(5):e2531. PubMed ID: 35380741
[TBL] [Abstract][Full Text] [Related]
10. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Zhou J; Tong F; Zhao J; Cui X; Wang Y; Wang G; Kang C; Liu X; Wang Q
Cancer Biol Med; 2023 Jun; 20(5):385-400. PubMed ID: 37283490
[TBL] [Abstract][Full Text] [Related]
11. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
12. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Sun W; Zhang W; Yu J; Lu Z; Yu J
Int J Neurosci; 2021 Oct; 131(10):975-983. PubMed ID: 32378973
[TBL] [Abstract][Full Text] [Related]
14. The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis.
Li XX; Xu JK; Su WJ; Wu HL; Zhao K; Zhang CM; Chen XK; Yang LX
Kaohsiung J Med Sci; 2024 Feb; 40(2):161-174. PubMed ID: 37873881
[TBL] [Abstract][Full Text] [Related]
15. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
16. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
[TBL] [Abstract][Full Text] [Related]
17. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
18. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
de Souza I; Monteiro LKS; Guedes CB; Silva MM; Andrade-Tomaz M; Contieri B; Latancia MT; Mendes D; Porchia BFMM; Lazarini M; Gomes LR; Rocha CRR
Cell Death Dis; 2022 Jul; 13(7):591. PubMed ID: 35803910
[TBL] [Abstract][Full Text] [Related]
19. C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis.
Huang S; Li J; Wu S; Zheng Z; Wang C; Li H; Zhao L; Zhang X; Huang H; Huang C; Xie Q
Oncogene; 2023 Apr; 42(17):1333-1346. PubMed ID: 36882524
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
